tiprankstipranks
Trending News
More News >
Aziyo Biologics (ELUT)
NASDAQ:ELUT
US Market
Advertisement

Aziyo Biologics (ELUT) AI Stock Analysis

Compare
70 Followers

Top Page

ELUT

Aziyo Biologics

(NASDAQ:ELUT)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 4o)
Rating:43Neutral
Price Target:
$1.50
▲(66.67% Upside)
Aziyo Biologics' overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While the earnings call highlighted some positive developments, the company's financial instability and valuation concerns weigh heavily on the score.
Positive Factors
Product Innovation
The strong growth of EluPro indicates successful product innovation and market acceptance, which can drive long-term revenue growth and strengthen market position.
Gross Margin Improvement
Improved gross margins reflect operational efficiencies and high-margin product lines, enhancing profitability and financial health over time.
Litigation Progress
Resolving the majority of litigation reduces legal expenses and strategic risks, allowing management to focus on growth and operational improvements.
Negative Factors
Financial Instability
Financial instability with negative equity and high liabilities limits the company's ability to invest in growth and may lead to funding challenges.
Revenue Decline
Declining revenue suggests challenges in market demand or competitive pressures, which can impact long-term growth prospects and market share.
Cash Flow Issues
Negative cash flows indicate potential liquidity issues, limiting the company's ability to fund operations and invest in future growth opportunities.

Aziyo Biologics (ELUT) vs. SPDR S&P 500 ETF (SPY)

Aziyo Biologics Business Overview & Revenue Model

Company DescriptionElutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
How the Company Makes MoneyAziyo Biologics makes money primarily through the sale of its biologic products to healthcare providers and medical device manufacturers. Its revenue model is based on direct sales and distribution agreements, where the company supplies its proprietary solutions that are used alongside medical devices to improve performance and patient compatibility. Significant partnerships with leading medical device companies enhance its market reach and distribution capabilities, contributing to its revenue growth. The company's earnings are also influenced by its ability to innovate and expand its product offerings in response to evolving medical needs and regulatory approvals.

Aziyo Biologics Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth and successful product launches, particularly with EluPro, alongside improved gross margins and progress in litigation settlements. However, challenges remain with SimpliDerm's performance and ongoing litigation issues.
Q2-2025 Updates
Positive Updates
EluPro Commercial Success
EluPro experienced 49% sequential growth this quarter, driven by 7 national GPO contracts and active ordering from 161 hospital systems. EluPro makes up 68% of BioEnvelope revenue, and sales per account are 130% higher compared to CanGaroo.
Awards and Recognition
Elutia received the Edison Award for Innovation in Medical Technology, two Medical Device Network Excellence Awards, and Dr. Michelle Williams won the Medical Device Innovator of the Year award.
BioEnvelope Revenue Growth
BioEnvelope revenue for the quarter increased by 33% year-over-year, reaching about a $14 million run rate, primarily driven by EluPro growth.
Litigation Progress
Elutia settled 97 out of 110 lawsuits stemming from a past product recall, significantly reducing future legal expenses and removing a strategic overhang.
Gross Margin Improvement
Adjusted gross margin increased to 62.4% for Q2, up from 58.4% a year ago, due to operational efficiencies and high margins in the cardiovascular segment.
Negative Updates
SimpliDerm Underperformance
SimpliDerm generated $2 million in revenue this quarter, which is lower than previous quarters, indicating a need for improved performance or strategic partnerships.
Litigation Legacy
Elutia is still dealing with 13 unresolved lawsuits related to a product recall from over four years ago, although progress is being made towards settlement.
Company Guidance
During Elutia's Second Quarter 2025 earnings call, the company provided robust guidance centered on the continued success and expansion of their EluPro product. EluPro saw a remarkable 49% sequential growth this quarter, with active ordering from 161 hospital systems. The company's strategic focus is on increasing the number of hospitals under contract through VACs and GPOs, which directly drives revenue. EluPro now constitutes 68% of the BioEnvelope revenue, with expectations to end the year at a $20 million revenue rate. Elutia also highlighted the upcoming NXT-41 platform for breast reconstruction, targeting a $1.5 billion U.S. market, and emphasized their ongoing strategic opportunities aimed at enhancing their cash position and business development. Gross margin improvements were noted, with the BioEnvelope business achieving a 62.4% adjusted gross margin, up over 4 percentage points from the previous year.

Aziyo Biologics Financial Statement Overview

Summary
Aziyo Biologics is facing significant financial challenges across all verticals. The income statement reflects declining revenues and substantial losses, while the balance sheet shows negative equity and high leverage. Cash flow remains negative, with slight improvements in free cash flow growth. The company needs to address these financial issues to improve its financial health and stability.
Income Statement
30
Negative
Aziyo Biologics shows declining revenue with a negative growth rate of -11.8% in TTM, indicating a challenging market environment. The company has negative profit margins, with a net profit margin of -90% and an EBIT margin of -73.85%, reflecting significant operational losses. The gross profit margin of 44.67% is relatively stable, but overall profitability remains a concern.
Balance Sheet
20
Very Negative
The balance sheet reveals financial instability, with a negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is negative due to negative equity, and the return on equity is positive only because of the negative equity, which is misleading. The equity ratio is also negative, highlighting financial distress.
Cash Flow
35
Negative
Cash flow analysis shows negative operating and free cash flows, though there is a slight improvement in free cash flow growth at 13.71% in TTM. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and accounting profits, but overall cash flow health is weak.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue23.68M24.38M24.75M23.85M47.39M42.68M
Gross Profit10.58M10.71M11.05M11.64M19.02M20.56M
EBITDA-14.01M-45.89M-31.92M-27.30M-15.72M-12.30M
Net Income-21.32M-53.95M-37.66M-32.90M-24.83M-21.82M
Balance Sheet
Total Assets33.85M36.13M43.43M68.84M67.17M82.81M
Cash, Cash Equivalents and Short-Term Investments8.50M13.24M19.28M16.99M30.39M39.15M
Total Debt28.24M24.74M23.95M39.40M23.24M52.31M
Total Liabilities75.69M82.39M82.03M73.87M53.65M61.98M
Stockholders Equity-41.84M-46.26M-38.60M-5.03M13.52M20.83M
Cash Flow
Free Cash Flow-33.27M-23.31M-22.11M-21.97M-15.99M-14.07M
Operating Cash Flow-32.79M-22.66M-21.76M-21.43M-15.62M-13.44M
Investing Cash Flow-1.03M-474.00K14.21M-540.00K-369.00K-640.00K
Financing Cash Flow24.14M17.09M9.84M9.00M6.71M51.02M

Aziyo Biologics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.90
Price Trends
50DMA
1.72
Negative
100DMA
1.82
Negative
200DMA
2.38
Negative
Market Momentum
MACD
-0.26
Positive
RSI
20.97
Positive
STOCH
8.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.72, and below the 200-day MA of 2.38, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 20.97 is Positive, neither overbought nor oversold. The STOCH value of 8.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELUT.

Aziyo Biologics Risk Analysis

Aziyo Biologics disclosed 77 risk factors in its most recent earnings report. Aziyo Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aziyo Biologics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
$111.09M-0.73-33.76%17.10%
44
Neutral
$153.02M-1.40-48.76%16.55%16.73%
43
Neutral
$37.53M149.62%-5.22%82.06%
36
Underperform
$258.18M-1.66-39.69%
33
Underperform
$268.58M-0.13-686.12%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ELUT
Aziyo Biologics
0.90
-2.89
-76.25%
TLSA
Tiziana Life Sciences
2.00
1.00
100.00%
ZNTL
Zentalis Pharmaceuticals
1.66
-1.71
-50.74%
CCCC
C4 Therapeutics
2.27
-3.11
-57.81%
VOR
Vor Biopharma
36.68
23.25
173.12%
KYTX
Kyverna Therapeutics, Inc.
6.08
1.45
31.32%

Aziyo Biologics Corporate Events

Business Operations and StrategyM&A Transactions
Elutia Sells Device Business to Boston Scientific
Positive
Sep 9, 2025

On September 8, 2025, Elutia Inc. entered into an agreement to sell its cardiac implantable electronic device business to Boston Scientific Corporation for $88 million. This transaction is expected to close in the fourth quarter of 2025 and will allow Elutia to focus on its drug-eluting biomatrix solutions in breast reconstruction, strengthen its financial position, and eliminate outstanding debt. The sale marks a strategic shift for Elutia, enabling it to advance its SimpliDerm franchise and drug-eluting pipeline without shareholder dilution, thereby enhancing long-term shareholder value.

The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Private Placements and Financing
Elutia Inc. Amends Credit Agreement with SWK Funding
Neutral
Aug 20, 2025

On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.

The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 11, 2025